Sangamo Therapeutics (SGMO) Reports Q2 Loss of $0.26

Sangamo Therapeutics (NASDAQ: SGMO) reported Q2 EPS of ($0.26), versus ($0.26) reported last year. Revenue for the quarter came in at $21.55 million, versus $17.55 million reported last year.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Ciena beats estimates on strong AI-driven demand, shares rise
• BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
• Victoria's Secret & Co. (VSXY) Tops Q2 EPS by 20c ; Offers Guidance